There is no FDA-approved treatment for AL amyloidosis; however, chemotherapy targeting plasma cells, such as cyclophosphamide, bortezomib (Velcade), and dexamethasone (CyBorD), and/or autologous stem cell transplant, are standard of care and can elicit deep and durable hematologic responses.7-9 Fig...
Amyloidosis is a disorder of protein folding in which normally soluble proteins are deposited extracellularly as insoluble fibrils, impairing tissue structure and function. Over 20 unrelated proteins form amyloid fibrils in vivo, with fibrils sharing a lamellar cross-β sheet structure, composed of non...
Amyloidosis: new strategies for treatment. Int J Biochem Cell Biol 35: 1608-1613 (2003).Hirschfield GM, Hawkins PN. Amyloidosis: new strategies for treatment. Int J Bioch Cell Biol. 2003;35:1608-13.Hirschfield, G.M.; Hawkins, P.N. Amyloidosis: New strategies for treatment. Int. J. ...
AmyloidosisresponsediagnosisprognosistherapyABSTRACTIntroduction: The most common form of systemic amyloidosis in Western countries is light chain amyloidosis. It is characterized by the deposition of a misfolded light chain... 查看全部>>doi:10.1080/17474086.2018.1424534Paolo Milani...
Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic his recent CAEL-101 findings, and how it can help shape treatment for patients living with amyloid light chain amyloidosis.
amyloidosis (hATTR).294,295,296Indeed, the rapid development of siRNA is benefit from lipid nanoparticles (LNPs) technology progress and related nucleic acid modification methods.297,298,299Researchers also use siRNAs for the treatment of autoimmune diseases and achieved some progress.300,301...
New treatment options are required for primary systemic amyloid light chain (AL) amyloidosis. This phase 1/2 dose-escalation study aimed to determine the m... G Moreau,A Jaccard,L Benboubker,... - PubMed 被引量: 303发表: 2010年 Combined Modality Therapy for Rectal Cancer The primary thera...
Thus, given the importance of Ca2+ and Zn2+ homeostasis for brain functioning, strategies aimed at restoring the brain balance of these ions are emerging as promising avenues for the treatment of AD with several therapeutic approaches based on the so-called ‘metals hypothesis’ already showing en...
Jonathan L. Kaufman, MD, discusses the significance of subcutaneous D-VCd in the treatment of patients with AL amyloidosis, remaining questions with the approach, and emerging strategies for those with high-risk cardiac features.
The New England Journal of Medicine (NEJM) is the world’s leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed research and interactive clinical content to physicians, educators, and the global medical community. 主办单位: ...